



senseiTM

BIO

Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

November 19, 2018

GAITHERSBURG, Md.--([BUSINESS WIRE](#))--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immunology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 1:30 p.m. ET in New York, NY.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine for the treatment of head and neck cancer and myelodysplastic syndrome, as well as other solid tumors and hematological cancers. SNS-301 targets a novel embryonic antigen and has successfully completed a Phase 1 clinical study. Sensei's precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.

Contacts

Media Contact:

Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact:

Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie@sternir.com